Table 2 Effectiveness of treatment across the two treatment groups as assessed by DAS28 and HAQ status and changes at 3 and 6 months
RTX 500 mg × 2 | RTX 1000 mg × 2 | Unadjusted p values (ANOVA) | Adjusted p values** | |
|---|---|---|---|---|
DAS28 baseline | 5.7 ± 1.3 (215) | 6.1 ± 1.3 (2069) | <0.0001 | |
DAS28 3 m | 4.4 ± 1.2 (138) | 4.2 ± 1.3 (1046) | 0.15 | |
DAS28 6 m | 4.3 ± 1.3 (109) | 4.3 ± 1.2 (1385) | 0.99 | |
DeltaDAS28 3 m | –1.3 ± 1.3 (125) | –1.9 ± 1.4 (991) | <0.0001 | 0.004 |
DeltaDAS28 6 m | –1.7 ± 1.4 (100) | –2.0 ± 1.3 (1344) | 0.02 | 0.23 |
HAQ baseline | 1.6 ± 0.7 (212) | 1.6 ± 0.7 (1584) | 0.48 | |
HAQ 3 m | 1.3 ± 0.7 (127) | 1.3 ± 0.7 (957) | 0.83 | |
HAQ 6 m | 1.2 ± 0.7 (109) | 1.3 ± 0.7 (912) | 0.21 | |
DeltaHAQ 3 m | –0.3 ± 0.5 (115) | –0.5 ± 0.6 (859) | 0.02 | 0.10 |
DeltaHAQ 6 m | -0.4 ± 0.6 (103) | –0.5 ± 0.7 (826) | 0.13 | 0.27 |